Compare CRNX & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | ROMA |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 134.6M |
| IPO Year | 2018 | 2022 |
| Metric | CRNX | ROMA |
|---|---|---|
| Price | $33.65 | $6.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $74.78 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 679.8K |
| Earning Date | 05-07-2026 | 12-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $722.66 | N/A |
| Revenue Next Year | $183.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.10 | $0.72 |
| 52 Week High | $57.99 | $11.77 |
| Indicator | CRNX | ROMA |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 55.28 |
| Support Level | $33.23 | $2.05 |
| Resistance Level | $37.23 | $8.73 |
| Average True Range (ATR) | 1.62 | 1.89 |
| MACD | 0.13 | 0.25 |
| Stochastic Oscillator | 8.33 | 37.20 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.